EMA accepts submission of Pfizer’s new arthritis drug
pharmafile | November 21, 2011 | News story | Research and Development, Sales and Marketing | EMA, Pfizer, tofacitinib
The European Medicines Agency has accepted Pfizer’s arthritis drug tofacitinib for review.
Tofacitinib is a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA). The EMA will now assess the drug and will aim to reach a decision next year.
Recent results from the Phase III ORAL study showed that the 10mg twice-daily dose showed statistically significant changes versus placebo in reducing signs and symptoms of RA, but the lower 5mg dose missed its primary endpoint.
If the drug reaches the market it will be competing with a number of established treatments, including Abbott’s Humira, J&J’s Remicade and Pfizer’s own Enbrel, which saw 2010 sales of $6 billion, $4.6 billion and $3.5 billion respectively.
All three are injectable forms of treatments, but whereas tofacitinib is taken as a pill twice-daily, Humira can be injected every other week and patients taking Enbrel must inject themselves twice a week.
J&J’s RA drug Remicade requires administration in hospital every eight weeks.
Ben Adams
Related Content
EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) …
EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …